# A nurse is caring for a client with beta-thalassemia major who requires regular blood transfusions. Which nursing intervention is the priority when preparing for blood transfusion therapy?

> source: MyMerci (mymerci.kr)  
> url: https://mymerci.kr/pages/nclex_q.php?qn_id=540797  
> language: ko  
> subject: Adult Health

## 문제

A nurse is caring for a client with beta-thalassemia major who requires regular blood transfusions. Which nursing intervention is the priority when preparing for blood transfusion therapy?

## 보기

1. Verify client identification and blood compatibility with another registered nurse **✔ 정답**
2. Premedicate the client with acetaminophen to prevent fever
3. Ensure the blood is warmed to room temperature before administration
4. Obtain baseline hemoglobin and hematocrit levels

**정답: 1**

## 해설

Verifying client identification and blood compatibility with another nurse is the priority to prevent fatal transfusion errors. Other actions are important but secondary to this critical safety step.

## 심화 해설

Understanding the Priority: Long-Term Complication Prevention

In clients with beta-thalassemia major (BTM), a genetic defect in hemoglobin production leads to severe anemia, making regular blood transfusions a life-sustaining necessity. However, the human body lacks an active physiologic mechanism to excrete the excess iron introduced with each unit of transfused red blood cells. Over time, this iron accumulates in vital organs—a condition known as transfusional iron overload [2]. While acute transfusion reactions are important to monitor for during the infusion, the most critical long-term nursing intervention is preventing the insidious and potentially fatal damage caused by iron deposition in the heart, liver, and endocrine glands [1].

Why Iron Chelation Therapy is the Priority

Without intervention, the accumulated iron generates free radicals, leading to oxidative stress and organ fibrosis. This results in life-threatening complications such as cardiomyopathy, liver cirrhosis, and diabetes mellitus [2]. Iron chelation therapy (ICT) works by binding to the excess iron in the body, allowing it to be excreted in urine or feces. Administering ICT as prescribed is the only way to prevent or delay this irreversible end-organ damage, making it the cornerstone of chronic management for transfusion-dependent thalassemia [1, 3].

Analysis of Other Options

To clarify why the other options are not the most important intervention in this context, consider the following distinctions:

- Option 1 (Monitor for hemolytic reactions): While essential during every transfusion, this is an acute safety measure. It does not address the cumulative, long-term risk that defines the chronic care of a client requiring repeated transfusions over a lifetime.

- Option 2 (Assess for splenomegaly): Splenomegaly is a common finding in BTM due to extramedullary hematopoiesis and red blood cell destruction. While important to assess, it is a complication of the disease process itself, not the primary, preventable consequence of the transfusion therapy.

- Option 4 (Encourage increased dietary iron): This intervention is contraindicated. Clients with BTM already have a pathologic iron-loading state from transfusions. Adding dietary iron would dangerously accelerate the development of iron overload and organ toxicity [2].

Clinical Application and Adherence Challenges

The effectiveness of ICT hinges on consistent adherence, which can be challenging due to the demanding nature of the therapy and its side effects [1]. A systematic review highlights that poor adherence directly correlates with adverse health outcomes, including elevated serum ferritin levels and increased organ iron concentration [3]. As a nurse, your role extends beyond simply administering the medication; it involves thorough education on the purpose of the therapy, monitoring for side effects, and assessing for barriers to adherence to ensure the client is protected from the devastating effects of iron overload [1, 3]. The goal of therapy is to maintain iron levels within a safe range, preventing the severe cardiac and hepatic complications that remain a leading cause of mortality in this population [2, 4].References (research sources)

- [1]Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.Research articleGeneen LJ, Dorée C, Estcourt LJ. (2023) · DOI: 10.1002/14651858.cd012349.pub3

- [2]Lessons from Beta-Thalassemia for Improving Iron Overload Monitoring and Management in Kidney Failure.Research articleNashwan AJ, Yassin M. (2025) · DOI: 10.7759/cureus.77620

- [3]A systematic review of adherence to iron chelation therapy among children and adolescents with thalassemia.Meta-analysis/systematic reviewReddy PS, Locke M, Badawy SM. (2022) · DOI: 10.1080/07853890.2022.2028894

## 임상 시나리오

Clinical Safety Guide: Blood Transfusion in Beta-Thalassemia Major

For patients with beta-thalassemia major who are transfusion-dependent, the risk of alloimmunization and hemolytic reactions increases with cumulative exposure. The bedside verification process is the most critical step to prevent catastrophic ABO incompatibility events.

- **Immediate Priority Action:** Two licensed nurses must independently verify the patient's identity using two identifiers (name, date of birth, medical record number) and confirm that the blood product label exactly matches the patient's blood bank armband and compatibility record at the bedside.

- **Vital Sign Monitoring Protocol:** Obtain baseline vital signs within 30 minutes prior to starting the transfusion. Remain with the patient for the first 15 minutes of the infusion, monitoring for signs of a hemolytic reaction (fever, chills, flank pain, hypotension).

- **Administration Guidelines:** Use a Y-type blood administration set with 0.9% normal saline only. Initiate the infusion slowly (2 mL/min) for the first 15 minutes. Complete the transfusion within 4 hours to prevent bacterial proliferation.

- **Management of Suspected Reaction:** If an acute hemolytic reaction is suspected, immediately stop the transfusion, maintain the IV line with normal saline, monitor vital signs, notify the provider, and return the blood product and tubing to the blood bank for repeat crossmatching and investigation.

**Key Safety Note:** Premedication or warming blood products should never delay or replace the dual-verification safety check. The most common cause of fatal transfusion reactions remains clerical error at the bedside.

## 핵심 개념

- **Beta-Thalassemia Major** — A severe inherited blood disorder characterized by defective hemoglobin production, leading to life-threatening anemia that requires lifelong regular blood transfusions for survival.
- **Acute Hemolytic Transfusion Reaction** — A life-threatening immune-mediated reaction caused by ABO-incompatible blood transfusion, resulting in rapid destruction of donor red blood cells, complement activation, and potential for shock, DIC, and acute kidney injury.
- **Dual Verification** — A mandatory safety protocol requiring two licensed professionals to independently confirm patient identity and blood product compatibility at the bedside to prevent human error in transfusion administration.

## 같은 주제 문제

- [A nurse is assessing a 25-year-old patient with beta-thalassemia major. Which assessment f…](https://mymerci.kr/pages/nclex_q.php?qn_id=540793)
- [A nurse is assessing a 25-year-old patient with beta-thalassemia major. Which assessment f…](https://mymerci.kr/pages/nclex_q.php?qn_id=540794)
- [A nurse is caring for a client with beta-thalassemia major who requires regular blood tran…](https://mymerci.kr/pages/nclex_q.php?qn_id=540795)
- [A nurse is caring for a client with beta-thalassemia major who requires regular blood tran…](https://mymerci.kr/pages/nclex_q.php?qn_id=540796)

---

More free questions: [기출문제](https://mymerci.kr/)

_학습 참고용입니다. 실제 임상은 최신 지침과 소속 기관 프로토콜을 따르세요._